SillaJen IPO Part 5 -Â Revenue & Valuation Estimates with Pexa-Vec's First Commercialization Year
We need to examine the size of SillaJen's expected sales in 2020, which is the reference year for its entire valuation. With an assumption that...
443 Views
SillaJen IPO Part 4 - IPO Price & Post-IPO Risks
SillaJen IPO price was set at ₩15,000, the lowest end of the indicative price band, after conducting the demand survey from (Nov 23-24) the...
373 Views
SillaJen IPO Part 3 - Competitive Strengths of Product (Pexa-Vec)
*Â In Part 3 (as below), I summarized the competitive strengths of product (Pexa-Vec).SillaJen's Pexa-Vec is an advanced liver cancer treatment...
339 Views
Recap of Samsung BioLogics' First Trading Day - Foreign Institutions Net Purchased 1M Shares
Samsung BioLogics closed at ₩144,000 with 6.67% gain on its first trading day. It started with a relatively weak sentiment at the opening price of...
327 Views
Samsung BioLogics' First Trading Day - Blunders in Barron's Argument & Price Prediction
As reported by Barron's on Nov 5 ("Samsung BioLogics IPO: Too Expensive"), there are still some skeptical views on BioLogics' IPO valuation....
405 Views